Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma

Publikation

Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma

Wissenschaftlicher Artikel/Review - 28.04.2008

Piguet Anne-Christine, Semela David, Keogh Adrian, Wilkens Ludwig, Stroka Deborah, Stoupis Christoforos, St-Pierre Marie V, Dufour Jean-François

Zitation

Piguet A, Semela D, Keogh A, Wilkens L, Stroka D, Stoupis C, St-Pierre M, Dufour J. Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. J Hepatol 2008; 49:78-87.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

J Hepatol 2008; 49

Veröffentlichungsdatum

28.04.2008

ISSN (Druck)

0168-8278

Seiten

78-87

Kurzbeschreibung/Zielsetzung

Hepatocellular carcinoma (HCC) is resistant to chemotherapy. We reported that sirolimus, an mTOR inhibitor, has antiangiogenic properties in HCC. Since antiangiogenic therapy may enhance chemotherapy effects, we tested the antitumorigenic properties of sirolimus combined with doxorubicin in experimental HCC.